Drugs / LFF269
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02047656 | Aug 2013 → Aug 2014 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01373086 | May → Oct 2011 | hypertensive disorder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LFF269 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02047656 ↗ |